Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment

“…During the discussion, 6 months were mentioned as an acceptable option for patients with a clinical reason for discontinuation. 20.8% of the panelists would never use neratinib in adjuvant treatment, 20.8% would use it in all ER+ N+ HER2+ patients, and 27.1% would use neratinib in ER+ HER2+ patients with ≥4 positive LNs [8]. 29.2% abstained from answering the question on adjuvant neratinib.…”

ABC4 Consensus: Assessment by a German Group of Experts

“…Given the APHINITY trial results [25] with the benefit of the dual blockade particularly in patients at high risk of recurrence (e.g., positive nodal status and negative steroid hormone receptor status), adjuvant application of dual HER2 blockade may be discussed as an option in patients with LABC. After 1 year of trastuzumab therapy, additional subsequent anti-HER2 therapy with neratinib could be considered in HR+/HER2+ breast cancer [26]. …”

GRB7 dependent proliferation of basal‐like, HER‐2 positive human breast cancer cell lines is mediated in part by HER‐1 signaling

“…In addition to trastuzumab, additional HER‐2 targeted therapeutics have been developed that showed great promise in various clinical scenarios and received regulatory approval. These include pertuzumab and ado‐trastuzumab emtansine (TDM1) and small molecule inhibitors such as lapatinib and neratinib . Amidst this remarkable success, there remains much room for improvement.…”